Knight Therapeutics enters exclusive distribution agreement with Kyowa Kirin for Poteligeo in Latin America
Knight Therapeutics says it will seek regulatory approval and then commercialize Poteligeo (mogamulizumab) in Brazil, Mexico, Colombia and Argentina under an exclusive distribution agreement with Kyowa Kirin International.
Sept. 29 (Reuters) - Knight Therapeutics Inc said it has entered into an exclusive distribution agreement with Kyowa Kirin International for Poteligeo (mogamulizumab). Under the pact, Knight Therapeutics will seek regulatory approval and commercialize Poteligeo in Brazil, Mexico, Colombia and Argentina.